TY - JOUR
T1 - Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis
AU - the Canadian Network for Autoimmune Liver Disease (CaNAL)
AU - Roberts, Surain B.
AU - Hirschfield, Gideon M.
AU - Worobetz, Lawrence J.
AU - Vincent, Catherine
AU - Flemming, Jennifer A.
AU - Cheung, Angela
AU - Qumosani, Karim
AU - Swain, Mark
AU - Grbic, Dusanka
AU - Ko, Hin Hin
AU - Peltekian, Kevork
AU - Selzner, Nazia
AU - Abrahamyan, Lusine
AU - Aziz, Bishoi
AU - Lytvyak, Ellina
AU - Tirona, Kattleya
AU - Gulamhusein, Aliya F.
AU - Janssen, Harry L.A.
AU - Montano-Loza, Aldo J.
AU - Mason, Andrew L.
AU - Hansen, Bettina E.
N1 - Funding Information:
Supported in part by unrestricted financial support from the Canadian Liver Foundation, Intercept Pharma Canada Inc., and the Toronto General & Western Hospital Foundation. The funders had no influence on the study design, data collection, analysis and interpretation of data, or the decision to submit for publication.
Publisher Copyright:
© 2022 American Association for the Study of Liver Diseases.
PY - 2022
Y1 - 2022
N2 - Background and Aims: We investigated associations between ethnicity, survival, and disease severity in a diverse Canadian cohort of patients with primary biliary cholangitis (PBC). Approach and Results: Patients with PBC were included from the Canadian Network for Autoimmune Liver Disease. Ethnicity was defined using a modified list adopted from Statistics Canada, and ethnicities with small samples were grouped. Clinical events were defined as liver decompensation, HCC, liver transplantation, or death. Clinical event–free and liver transplantation–free survival were analyzed using Cox regression. Trajectories of serum liver function tests were assessed over time using mixed-effects regression. Health-related quality of life was assessed using the Short Form 36, the PBC-40 questionnaire, and the 5-D Itch scale and analyzed using mixed-effects regression. The cohort included 1538 patients with PBC from six sites and was comprised of 82% White, 4.7% Indigenous, 5.5% East Asian, 2.6% South Asian, and 5.1% miscellaneous ethnicities. Indigenous patients were the only ethnic group with impaired liver transplant–free and event-free survival compared to White patients (HR, 3.66; 95% CI, 2.23–6.01; HR, 3.09; 95% CI, 1.94–4.92). Indigenous patients were more likely to have a clinical event before diagnosis (10%) than all other ethnic groups despite similar age at diagnosis. Indigenous patients presented with higher alkaline phosphatase, total bilirubin, and GLOBE scores than White patients; and these relative elevations persisted during follow-up. Conclusions: Indigenous Canadians with PBC present with advanced disease and have worse long-term outcomes compared to White patients.
AB - Background and Aims: We investigated associations between ethnicity, survival, and disease severity in a diverse Canadian cohort of patients with primary biliary cholangitis (PBC). Approach and Results: Patients with PBC were included from the Canadian Network for Autoimmune Liver Disease. Ethnicity was defined using a modified list adopted from Statistics Canada, and ethnicities with small samples were grouped. Clinical events were defined as liver decompensation, HCC, liver transplantation, or death. Clinical event–free and liver transplantation–free survival were analyzed using Cox regression. Trajectories of serum liver function tests were assessed over time using mixed-effects regression. Health-related quality of life was assessed using the Short Form 36, the PBC-40 questionnaire, and the 5-D Itch scale and analyzed using mixed-effects regression. The cohort included 1538 patients with PBC from six sites and was comprised of 82% White, 4.7% Indigenous, 5.5% East Asian, 2.6% South Asian, and 5.1% miscellaneous ethnicities. Indigenous patients were the only ethnic group with impaired liver transplant–free and event-free survival compared to White patients (HR, 3.66; 95% CI, 2.23–6.01; HR, 3.09; 95% CI, 1.94–4.92). Indigenous patients were more likely to have a clinical event before diagnosis (10%) than all other ethnic groups despite similar age at diagnosis. Indigenous patients presented with higher alkaline phosphatase, total bilirubin, and GLOBE scores than White patients; and these relative elevations persisted during follow-up. Conclusions: Indigenous Canadians with PBC present with advanced disease and have worse long-term outcomes compared to White patients.
UR - http://www.scopus.com/inward/record.url?scp=85133541649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133541649&partnerID=8YFLogxK
U2 - 10.1002/hep.32426
DO - 10.1002/hep.32426
M3 - Article
C2 - 35220609
AN - SCOPUS:85133541649
SN - 0270-9139
JO - Hepatology
JF - Hepatology
ER -